Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710.
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1603-1612. doi: 10.1073/pnas.1816030116. Epub 2019 Jan 17.
Current therapeutic interventions for the treatment of respiratory infections are hampered by the evolution of multidrug resistance in pathogens as well as the lack of effective cellular targets. Despite the identification of multiple region-specific lung progenitor cells, the identity of molecules that might be therapeutically targeted in response to infections to promote activation of progenitor cell types remains elusive. Here, we report that loss of specifically in SCGB1A1-expressing cells leads to a significant increase in the proliferation and differentiation of bronchiolar epithelial cells, resulting in dramatic expansion of an SCGB1A1+ airway cell population that coexpresses SPC, a marker for type II alveolar cells that promotes alveolar regeneration following bacterial pneumonia. Furthermore, treatment with an Abl-specific allosteric inhibitor enhanced regeneration of the alveolar epithelium and promoted accelerated recovery of mice following pneumonia. These data reveal a potential actionable target that may be exploited for efficient recovery after pathogen-induced infections.
目前,治疗呼吸道感染的方法受到病原体多药耐药性的发展以及缺乏有效细胞靶点的阻碍。尽管已经鉴定出多种特定于肺部的祖细胞,但对于可能在感染时通过激活祖细胞类型来促进治疗的分子的身份仍然难以捉摸。在这里,我们报告说,特异性缺失会导致细支气管上皮细胞的增殖和分化显著增加,导致 SCGB1A1+气道细胞群的急剧扩张,该细胞群共表达 SPC,这是 II 型肺泡细胞的标志物,可促进细菌性肺炎后肺泡的再生。此外,用 Abl 特异性别构抑制剂治疗可增强肺泡上皮的再生,并促进肺炎后小鼠的快速恢复。这些数据揭示了一个潜在的可操作靶点,可用于在病原体感染后实现有效的恢复。